• Actinium Pharmaceuticals disclosed two newly issued U.S. patents tied to Actimab-A use in solid tumors by targeting myeloid-derived suppressor cells.
• Patents include US 12,491,274 covering sarcoma treatment, expiring Oct. 15, 2043, and US 12,539,340 covering solid tumors, expiring Oct. 31, 2043.
• Another U.S. patent, US 12,410,249, issued for Actimab-A in low peripheral blast AML, with a term to Oct. 12, 2039.
• Patent applications covering Actimab-A combinations with venetoclax or CLAG-M advanced in Canada, with additional applications pending in several regions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608141702PR_NEWS_USPR_____NY26410) on August 14, 2026, and is solely responsible for the information contained therein.